The global Antinuclear Antibody Test Market size is expected to reach USD 2.36 billion by 2025, according to a new report by Grand View Research, Inc. It is anticipated to expand at a CAGR of 12.5% over the forecast period. Rising adoption of ANA test coupled with government initiatives to treat autoimmune disorders is likely to drive the market. Furthermore, rising incidence of autoimmune disorders is projected to fuel the growth.
Antinuclear
Antibody (ANA) testing is an important tool to diagnose and manage autoimmune
diseases such as Systemic Lupus Erythematosus (SLE) and rheumatoid arthritis.
According to the Lupus Foundation of America, at least 5 million people
globally and around 1.5 million people in U.S. have a form of lupus. Around
16,000 new cases are registered every year. The disease mostly affects women of
childbearing age. SLE accounts for almost 70% of all cases of lupus. The high
prevalence of autoimmune disorders is one of the factors driving the market.
Extension
of ANA from a test for SLE to a test for any autoimmune diseases has boosted
the usage of antinuclear antibody testing. An increase in ANA demand may also
be due to the factors such as expanded role of primary care physicians in
healthcare delivery systems. In addition, rising R&D activities and
government initiatives regarding early diagnosis of autoimmune disorders have
triggered the demand for ANA tests.
Request
a sample copy or view summary of this report@
https://www.grandviewresearch.com/industry-analysis/antinuclear-antibody-ana-test-market
Further key findings from the study suggest:
- Reagents and
assay kits was the largest segment in 2017. It is likely to witness
fastest growth over the forecast period due to wide usage and rise in a
number of reagent rental agreements
- Immunofluorescence
assay led the market in terms of market share in 2017 owing to superior
sensitivity compared to other available techniques
- ELISA is
expected to be the fastest growing segment over the forecast period.
Increasing adoption of these tests is attributed to easy automation and
handling without high level of operator skill
- Rheumatoid
arthritis segment is projected to hold largest market share, mainly due to
high prevalence of the disease
- North
America was the largest region in terms of revenue in 2017, followed by
Europe. Both are the most well-established regions in terms of the
adoption of ANA testing and make up most of the existing market
- Asia Pacific
is likely to be the fastest growing region over the forecast period due to
unmet clinical needs and need for better diagnosis. Rising government
initiatives and clinical research activities for advanced diagnostics are
expected to further fuel growth
- Key players
operating in the antinuclear antibody test market are Thermo Fisher
Scientific Inc.; Alere Inc.; Bio-Rad Laboratories; Trinity Biotech PLC;
Zeus Scientific, Inc.; Inova Diagnostics; Immuno Concepts; Erba
Diagnostics, Inc.; Euroimmun AG; and Antibodies Inc.
- Key companies
are adopting R&D, geographic expansion, and collaborations to gain
market share.
Grand View Research, Inc. is a U.S. based market research and consulting company, registered in the State of California and headquartered in San Francisco. The company provides syndicated research reports, customized research reports, and consulting services. To help clients make informed business decisions, the company offers market intelligence studies ensuring relevant and fact-based research across a range of industries including technology, chemicals, materials, healthcare and energy.
Contact:
Sherry James
Corporate Sales Specialist, USA
Grand View Research, Inc
Phone: 1-415- 349-0058
Toll Free: 1-888- 202-9519
Email: sales@grandviewresearch.com
For More Information: https://www.grandviewresearch.com
No comments:
Post a Comment